Stent Grafts Provided Superior Primary Patency for Central Venous Stenosis Treatment in Comparison with Angioplasty and Bare Metal Stent

2016 ◽  
Vol 50 (4) ◽  
pp. 221-230 ◽  
Author(s):  
Pietro Quaretti ◽  
Franco Galli ◽  
Lorenzo Paolo Moramarco ◽  
Riccardo Corti ◽  
Giovanni Leati ◽  
...  
Keyword(s):  
Bare Metal Stent ◽  
Primary Patency ◽  
Bare Metal ◽  
Metal Stent ◽  
Stent Grafts ◽  
Central Venous ◽  
Central Venous Stenosis ◽  
Venous Stenosis

scholarly journals Comparison of Management for Central Venous Stenosis With or Without Previous Catheter Placement

2021 ◽  
Vol 12 ◽  
Author(s):  
Wei Ma ◽  
Zhengde Zhao ◽  
Qining Fu ◽  
Liangzhu Hu ◽  
Xia Zhao ◽  
...  
Keyword(s):  
Patency Rate ◽  
Bare Metal Stent ◽  
Primary Patency ◽  
Catheter Placement ◽  
Bare Metal ◽  
Metal Stent ◽  
Central Venous ◽  
Primary Patency Rate ◽  
Central Venous Stenosis ◽  
Venous Stenosis

Objective: To compare central venous stenosis/occlusion with or without previous jugular catheter placement history.Methods: Data of patients with central vein stenosis/occlusion receiving endovascular intervention in our hospital from January 2015 to December 2018 were collected and analyzed.Results: Twenty-nine patients with previous jugular catheter placement history (CVC group) and 33 patients (excluded two with technical failure) without such history (non-CVC group) are included in this study. Previous jugular catheter placement history raised the risk of postintervention recurrence 1.02 times (CVC group vs. non-CVC group, HR = 2.02 95%CI: 0.91–4.48). The primary patency rate at 6, 12, 18, and 24 months was 76.9, 54.2, 45.5, and 25.0% separately in the CVC group and 80.6, 70.0, 67.9, and 44.4% separately in the non-CVC group. The assisted primary patency rate at 6, 12, 18, and 24 months was 92.3, 91.7, 86.4, and 68.8% separately in the CVC group and 93.5, 90.0, 82.1, and 61.1% separately in the non-CVC group. Patients in the CVC group received a higher frequency of reintervention (0.7 times/year/patient vs. 0.3 times/year/patient). There was no significant difference in the assisted primary patency rate between the two groups. Different primary interventions (angioplasty alone, bare metal stent, stent graft) did not affect primary patency and assisted primary patency, but percutaneous transluminal stenting (PTS) with a bare metal stent had a significant lower primary patency rate between 3 and 24 months compared with PTS with a stent graft (p = 0.011).Conclusion: Central venous stenosis/occlusion with a previous jugular catheter placement history develops symptoms earlier and had a worse prognosis after endovascular intervention. More efforts are needed to carry out end-stage kidney disease life plan to reduce the harm of evitable catheter placement.

Primary and secondary patencies of transposed femoral vein fistulas are significantly greater than with the HeRO graft

2017 ◽  
Vol 18 (3) ◽  
pp. 232-237 ◽  
Author(s):  
Eric D. Ladenheim ◽  
Dzenan Lulic ◽  
Craig Lum ◽  
Sid Agrawal
Keyword(s):  
Wound Healing ◽  
Femoral Vein ◽  
Primary Patency ◽  
Secondary Patency ◽  
Central Venous ◽  
Av Fistula ◽  
Central Venous Stenosis ◽  
Venous Stenosis ◽  
One Year ◽  
The One

Introduction For access-challenged patients with bilateral upper extremity central venous stenosis, solutions include the Hemodialysis Reliable Outflow (HeRO) device or an autogenous AV fistula in the lower limb. We evaluated HeRO grafts and transpositions of the femoral vein in maintaining primary and secondary patency. Methods We retrospectively analyzed 40 patients with a HeRO device and 18 patients with superficial femoral artery to transposed femoral vein autogenous arteriovenous fistula (SFA-tFV). All patients had bilateral central venous obstruction. All procedures were outpatient performed by a single surgeon at one center between 2009-2015. Operative details, intraoperative flows, and flows at the first-week postoperative visit were analyzed, as were primary and secondary patency and intervention rates. Complications were compared between groups. Results The one-year cumulative primary patency was 30% for HeRO grafts and 79% for SFA-tFV fistulas (p = 0.0001); secondary patency was 71% for HeRO grafts and 93% for SFA-tFV fistulas (p = 0.03). To maintain patency, HeRO patients required a mean 2.1 interventions per year and thigh fistula patients required a mean 0.4 interventions per year. Thirty-seven percent of thigh fistula patients had a hematoma or seroma versus 5% of HeRO patients and 17% of thigh fistula patients experienced delayed wound healing versus 2.5% of HeRO patients (p<0.05). None of the thigh fistula patients had distal ischemia. Conclusions HeRO patients had lower primary and secondary patency rates versus thigh fistula patients and HeRO grafts required five-fold more interventions to maintain secondary patency. However, patients with thigh fistulas had significantly more wound healing problems. Thus, the SFA-tFV has become our access of choice for patients with bilateral central venous stenosis.

scholarly journals Primary Patency Rates of Endovascular Interventions in Hemodialysis Patients with Central Venous Stenosis and Occlusions

2021 ◽  
Vol 1 (1) ◽  
pp. 17-21
Author(s):  
Mehmet Burak Çildağ ◽  
Veli Süha Öztürk ◽  
Recep Özgür ◽  
Ömer Faruk Kutsi Köseoğlu
Keyword(s):  
Hemodialysis Patients ◽  
Primary Patency ◽  
Central Venous ◽  
Central Venous Stenosis ◽  
Endovascular Interventions ◽  
Venous Stenosis

scholarly journals Giant aneurysm in medial anterior descending artery: treatment with two endovascular stent grafts on bare metal stent scaffold

2011 ◽  
Vol 2 ◽  
pp. 173-177
Author(s):  
Marek Król ◽  
Bartosz Skwarna ◽  
Grzegorz Gałuszka ◽  
Radosław Szymański ◽  
Paweł Buszman
Keyword(s):  
Giant Aneurysm ◽  
Bare Metal Stent ◽  
Bare Metal ◽  
Endovascular Stent ◽  
Metal Stent ◽  
Stent Grafts

Combining the Passeo-18 Lux Drug-Coated Balloon and the Pulsar-18 Bare Metal Stent: 12- and 24-Month Outcomes of the BIOLUX 4EVER Investigator-Initiated Trial

2020 ◽  
Vol 27 (6) ◽  
pp. 936-945
Author(s):  
Koen Deloose ◽  
Marc Bosiers ◽  
Patrick Peeters ◽  
Jürgen Verbist ◽  
Lieven Maene ◽  
...  
Keyword(s):  
De Novo ◽  
Ankle Brachial Index ◽  
Bare Metal Stents ◽  
Bare Metal Stent ◽  
Primary Patency ◽  
Metal Stents ◽  
Bare Metal ◽  
Metal Stent ◽  
Drug Coated Balloon

Purpose: To report the outcomes after treating stenotic or occluded femoropopliteal lesions with a drug-coated balloon (DCB) followed by the implantation of a thin-strut self-expanding bare metal stent in the BIOLUX 4EVER trial ( ClinicalTrials.gov identifier NCT02211664). Materials and Methods: The prospective, multicenter, physician-initiated BIOLUX 4-EVER trial was conducted at 5 centers in Belgium and enrolled 120 patients (mean age 70.9±10.5 years; 79 men) with symptomatic stenotic or occluded de novo femoropopliteal lesions. A fifth of the patients had diabetes mellitus and nearly half had previous peripheral artery interventions. The lesions were a mean 83.3±49.5 mm long with a mean reference vessel diameter of 5.26±0.59 mm. Lesions were treated with a Passeo-18 Lux DCB followed by the implantation of a Pulsar-18 bare metal stent. Follow-up visits were conducted at 1, 6, 12, and 24 months postprocedure; the main outcome was primary patency at 12 months. Results: Technical success was obtained in all patients. Primary patency was observed in 89.9% of patients (95% CI 84.0% to 95.8%) at 12 months and in 83.5% at 24 months (95% CI 89.9% to 97.3%), and freedom from target lesion revascularization was 93.6% (95% CI 89.9% to 97.3%) and 86.1% (95% CI 79.9% to 92.3%), respectively. Ten patients died throughout the course of the trial (90.7% survival at 24 months), all of noncardiovascular causes. The ankle-brachial index improved from 0.68±0.09 at baseline to 0.93±0.11 and 0.93±0.12 at 12- and 24-month follow-up visits (p<0.001). An improvement of at least 1 Rutherford category was observed in 91 of 94 patients (96.8%) at 12 months and 78 of 83 patients (93.4%) at 24 months (p<0.001). Conclusion: The combination of a Passeo-18 Lux DCB followed by a Pulsar-18 stent implantation produced safe and effective outcomes in the treatment of femoropopliteal lesions at up to 24 months. Adding paclitaxel to the bare nitinol stent platform by predilating with a Passeo-18 Lux DCB seems to increase efficacy at 1 and 2 years compared with the use of bare metal stents only, which were investigated in the precursor 4-EVER study.

Sign in / Sign up

Export Citation Format

Share Document